Focus: Noven is a specialty pharmaceutical company headquartered in Miami focused on small-molecule transdermal and innovative delivery systems. The company operates as a established player with a portfolio of marketed products in neurology, women's health, and pain management.
Profile data last refreshed 2h ago · AI intelligence enriched 2w ago
Hot — 48 jobs added in 30d
Net +37 (48 new, 11 removed). Aggressive expansion phase.
Best suited for candidates seeking stability in a niche delivery-focused company, but career upside is limited by portfolio concentration risk and modest pipeline catalysts.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Accounts for 71% of company revenue but faces exclusivity cliff with no disclosed LOE date, creating material long-term risk.
Help build intelligence for Noven Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Noven Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Second-largest revenue driver with LOE approaching 2030; represents diversified women's health franchise with multiple delivery formats.
Established transdermal ADHD therapy with pipeline follow-on programs, but revenue modest and approaching exclusivity.
Lowest revenue contributor but has longest patent life (2042), demonstrating portfolio longevity in ADHD indication.
6 discontinued, 3 duplicate formulations not shown
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo